Johnson & Johnson (NYSE:JNJ) has announced that the investigational antihypertensive drug aprocitentan significantly lowered blood pressure (BP) when used in conjunction with background antihypertensive therapy in the Phase 3 PRECISION study.
Sharing the results in collaboration with Idorsia (OTCMKTS:IDRSF), J&J noted that the drug candidate helped maintain a reduction in blood pressure for 48 weeks.
Aprocitentan is a novel dual endothelin receptor antagonist (ERA).
The companies presented the data in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2022. The data were also published in The Lancet.
Scientists have noted the role of the endothelin pathway in hypertension, but aprocitentan is among the first drug candidates to target the pathway.
“The results of PRECISION demonstrate aprocitentan is a novel and generally well-tolerated potential treatment strategy for resistant hypertension…